ID | 11642 |
Eprint ID | 11642
|
FullText URL | |
Title Alternative | ピルフェニドンは反復抗原暴露により起こる気道過敏性,気道炎症および気道リモデリングを制御する
|
Author |
Hirano, Atsushi
|
Abstract | We investigated the therapeutic potential of a newly developed antifibrotic agent, pirfenidone, to regulate airway remodeling and the development of allergic airway inflammation and airway hyperresponsiveness after chronic allergen challenge. Administration of pirfenidone after sensitization but during the period of ovalbumin challenge significantly prevented the development of airway hyperresponsiveness and prevented eosinophil and lymphocyte accumulation in the airways. IL-4, IL-5, and IL-13 levels in bronchoalveolar lavage fluid and ovalbumin-specific serum IgE antibody levels were also significantly reduced. Treatment with pirfenidone significantly reduced transforming growth factor-beta1 and platelet-derived growth factor levels in bronchoalveolar lavage fluid. Pirfenidone reduced the expression of transforming growth factor-beta1, the development of goblet cell hyperplasia and subepithelial collagenization, and the increases in contractile elements in the lung. These data indicate that pirfenidone may play an important role in the treatment of asthma and has the potential reduce or prevent airway remodeling.
|
Keywords | Mutation
Carcinogenesis
Multivariate analysis
Case-control study
|
Note | http://dx.doi.org/10.1165/rcmb.2005-0452OC
|
Published Date | 2007-03-23
|
Publication Title | |
Content Type |
Thesis or Dissertation
|
Grant Number | 甲第3300号
|
Granted Date | 2007-03-23
|
Thesis Type |
Doctor of Philosophy in Medical Science
|
Grantor | 岡山大学
|
Official Url | http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16675785&dopt=Abstract
|
language |
Japanese
|
File Version | none
|
Refereed |
Unknown
|